Abstract A015: JAB-BX600, a first-in-class EGFR-directed antiboEdy drug conjugate delivering a novel KRAS G12D inhibitor
In contrast to non-small cell lung cancer and pancreatic cancer, KRAS inhibitors exhibited limited single agent activities in colorectal cancer (CRC), largely owing to EGFR-mediated adaptive MAPK pathway reactivation and intratumor heterogeneity. JAB-BX600, a humanized, EGFR-targeted antibody-drug conjugate (ADC)...